Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00486421 · ClinicalTrials.gov registry record · Early Phase 1
Rituximab and Prednisone as First-Line Therapy in Treating Patients With Immune Thrombocytopenic Purpura
A Early Phase 1 study, sponsored by Mayo Clinic.
- Completed
- Registry status
- Early Phase 1
- Development phase
- 22
- Enrollment target
NCT00486421: Completed Early Phase 1 study, sponsored by Mayo Clinic.
NCT00486421 is a Early Phase 1 study that has completed, run by Mayo Clinic. The registered enrollment target is 22 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00486421, a Early Phase 1 study, has completed, sponsored by Mayo Clinic.
- COMPLETED
- Registry status
- Early Phase 1
- Development phase
- 22 participants
- Enrollment target
Study Summary
RATIONALE: Rituximab and prednisone may increase the number of platelets in patients with immune thrombocytopenic purpura. PURPOSE: This phase II trial is studying the side effects and how well giving rituximab together with prednisone works as first-line therapy in treating patients with immune thrombocytopenic purpura.
Interventions
- DRUG Prednisone
- BIOLOGICAL Rituximab
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 22 participants |
| Start Date | 2007-01 |
| Est. Completion | 2008-11 |
| Phase | Early Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00486421
The ClinicalTrials.gov registry entry for NCT00486421 describes a study currently listed as completed, categorized as Early Phase 1. The registered enrollment target is 22 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Mayo Clinic, which has 2,844 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Prednisone is the first listed.
NCT00486421 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00486421 about?
NCT00486421 is a clinical study titled "Rituximab and Prednisone as First-Line Therapy in Treating Patients With Immune Thrombocytopenic Purpura". RATIONALE: Rituximab and prednisone may increase the number of platelets in patients with immune thrombocytopenic purpura. PURPOSE: This phase II trial is studying the side effects and how well giving rituximab together with prednisone works as first-line therapy in treating patients with immune th...
What is the current status of trial NCT00486421?
This trial is currently completed. It is a Early Phase 1 study. The enrollment target is 22 participants. The study started on 2007-01. Estimated completion is 2008-11.
What interventions are being tested in trial NCT00486421?
The interventions under investigation include: Prednisone (DRUG), Rituximab (BIOLOGICAL).
Who is sponsoring clinical trial NCT00486421?
This trial is sponsored by Mayo Clinic, which has 2,844 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.